caplacizumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
humanized origin	5308	915810-67-2

Description:

Molecule	Description
Synonyms: caplacizumab ALX-0081 ALX-0681 calibvi caplacizumab-yhdp	In patients with aTTP, levels of a substance called von Willebrand factor are increased. von Willebrand factor acts on platelets to cause them to stick together and form blood clots. Caplacizumab, the active substance in Cablivi, is a nanobody (a small antibody) which has been designed to attach to von Willebrand factor in a way that stops it acting on platelets. This reduces platelets sticking together and forming clots in blood vessels and, as a result, platelet levels in the blood rise because they are no longer taken up to form clots. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

caplacizumab
ALX-0081
ALX-0681
calibvi
caplacizumab-yhdp

In patients with aTTP, levels of a substance called von Willebrand factor are increased. von Willebrand factor acts on platelets to cause them to stick together and form blood clots. Caplacizumab, the active substance in Cablivi, is a nanobody (a small antibody) which has been designed to attach to von Willebrand factor in a way that stops it acting on platelets. This reduces platelets sticking together and forming clots in blood vessels and, as a result, platelet levels in the blood rise because they are no longer taken up to form clots.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
10	mg	P

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Aug. 30, 2018	EMA	ABLYNX NV
Feb. 6, 2019	FDA	ABLYNX NV

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
ADAMTS13 activity decreased	118.35	58.42	13	260	88	50604763

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
ADAMTS13 activity decreased	141.70	51.66	16	328	145	64498243
ADAMTS13 activity abnormal	89.23	51.66	8	336	0	64498388
Platelet count decreased	56.64	51.66	24	320	167687	64330701

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	B01AX07	BLOOD AND BLOOD FORMING ORGANS ANTITHROMBOTIC AGENTS ANTITHROMBOTIC AGENTS Other antithrombotic agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Thrombotic thrombocytopenic purpura	indication	78129009	DOID:10772

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
von Willebrand factor	Unclassified	P04275	VWF_HUMAN	ANTIBODY BINDING	Kd	8.51		IUPHAR	DRUG LABEL

External reference:

ID	Source
2R27AB6766	UNII
C3713057	UMLSCUI
CHEMBL2109624	ChEMBL_ID
DB06081	DRUGBANK_ID
D11160	KEGG_DRUG
9123	IUPHAR_LIGAND_ID
2110604	RXNORM
36266	MMSL
d09171	MMSL
784411004	SNOMEDCT_US
789447000	SNOMEDCT_US
4038197	VANDF
4038198	VANDF
017896	NDDF
C585343	MESH_SUPPLEMENTAL_RECORD_UI
9511	INN_ID

Pharmaceutical products:

None